Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Genentech, Inc.
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Rutgers, The State University of New Jersey
Acepodia Biotech, Inc.
Xencor, Inc.
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
STCube, Inc.
Corvus Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey
Emory University
Klus Pharma Inc.
Endocyte
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Pfizer
MacroGenics
Incyte Corporation
MacroGenics
Shionogi Inc.
Seagen Inc.
Seagen Inc.
Bayer
Celgene
Zhujiang Hospital
Dartmouth-Hitchcock Medical Center
University of Kansas Medical Center
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Santa Maria Biotherapeutics
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Fox Chase Cancer Center
OHSU Knight Cancer Institute
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc